Maxim downgraded NeuroSense (NRSN) to Hold from Buy.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NRSN:
- NeuroSense Receives FDA Approval for Phase 3 Study of ALS Treatment
- NeuroSense concludes Type C meeting with FDA for PrimeC treatment
- NeuroSense files to sell 6.6M ordinary shares for holders
- NeuroSense’s PrimeC Shows Promise in ALS Treatment
- NeuroSense announces ‘positive’ results from the PARADIGM study
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue